Legends to Appendix Figures
Appendix Figure S1 . Validation of the siRNA-based screening (a-c) MDA-MB-231 cells were transfected with scrambled siRNA (siNC) or siRNAs against MT1-MMP, N-WASP, or TKS5, and cultured on optical microplates coated with gelatin conjugated with Oregon Green R 488 for two days in the presence of GM6001 to avoid gelatin degradation. Then the cells were incubated with media without GM6001 for 24 hours to promote gelatin degradation. Degradation activity was measured by counting the population of cells on degraded gelatin as dark black foci. Representative merged images of degraded Oregon green gelatin (green) with TRITC-phalloidin (red) and DAPI (blue) are shown (a). Data are means ± SEM (b, error bars; n > 100 cells/experiment in three independent ones). Efficacy of targeted gene silencing was verified by qPCR (c). Bar, 50 µm. *, P < 0.05, **, P < 0.01, ***, P < 0.001.
Appendix Figure S2 . RAB2A is genetically amplified in breast tumors and highly expressed in breast cancer cell lines (a) RAB2A is amplified in various tumors. The cBio Cancer Genomics Portal (http://www.cbioportal.org/public-portal/) was queried for RAB2A across various tumor datasets. The alteration frequency, types of alterations of RAB2A, availability of mutation analysis, and Copy Number Alteration (CNA) in the various tumor cohorts are shown.
(b) RAB2A is the most frequently amplified gene in invasive breast carcinoma among the candidate RAB GTPases identified in our screens. The percentage of each RAB gene amplification in invasive breast carcinoma reported in the Cancer Genome Atlas (TCGA) is shown.
(c) 50 µg of total cell lysate from breast derived cell line as indicated below was immunoblotted by anti-RAB2A and anti-tubulin antibodies.
Appendix Figure S3 . Immunohistochemistry analysis of RAB2A in human breast cancers (a) Specificity test for the anti-RAB2A antibody. Doxycycline-inducible empty vector (EV), RAB2A-shRNA (shRAB2A), and RAB2A-expression (RAB2A overexpression) MCF10.DCIS.com cells were cultured in the presence of doxycycline for three days. Cells were formalin fixed, paraffin embedded and tested by IHC at a dilution of 1:100 following an antigen retrieval procedure in Citrate pH 6.0. Cytoplasmic RAB2A signal is lost in silenced cells and clearly evident in overexpressing cells, with respect to EV MCF10A cells. (b) A TMA core with both cancer (T) and normal breast (N) tissues. RAB2A expression is obviously more elevated in tumor cells with respect to invasive neoplastic cells. (c) Kaplan-Meier and univariate Cox proportional regression analysis of RAB2A expression. Expression IHC score class "Low" and "Moderate" are not significantly different in predicting distant relapse, and are both statistically different from class "High". Based on this analysis we group the sample in two categories low+moderate and high RAB2A expresser.
Appendix Figure S4 . Loss of RAB2A has no impact on the amount of secreted metalloproteases and surface MT1-MMP (a, b) Serum-starved MDA-MB-231 (a) and MCF10.DCIS.com (b) cells transfected with scrambled siRNA (siNC) or siRNA against RAB2A (siRAB2A #1 and #2 correspond in Figure   1b ) were incubated in the absence (NT) or presence of 100 ng/ml HGF. Identical aliquots of medium were collected, and secreted matrix metalloproteases and TIMPs by these cells were quantified by using Quantibody Human MMP Array 1 R . Induction of cytokines in the medium by HGF was expressed as a ratio between HGF and NT. The ratio of cytokines in HGF-treated/untreated siNC cells was set as 1.
(c-g) Gelatin zymography analysis. Serum-starved MCF10.DCIS.com cells transfected with siNC or siRAB2A were incubated in the absence (-) or presence (+) of 100 ng/ml HGF. Aliquots of medium were collected, and analyzed by gelatin zymography. Representative zymogram shows bands of MMP2 and MMP9 (c). Induction of MMP2 and MMP9 by HGF was expressed as a ratio between HGF and NT (d). Efficacy of RAB2A silencing was verified and mRNA level of MMP2 and MMP9 were quantified by qPCR (e-g). 
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